Rockwell Medical In (RMTI) 7.21 $RMTI
Rockwell Medical Enters into Exclusive License Agreement with ARAM Medical to Commercialize Triferic(R) in Saudi Arabia, Egypt and Middle East Territories
GlobeNewswire - Tue Aug 16, 7:00AM CDT
- Territory Covers 375,000 CKD-HD patients; Rockwell Receives Upfront Licensing Fee,
RMTI: 7.21 (-0.01)
Rockwell Medical Reports Second Quarter Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2016.
RMTI: 7.21 (-0.01)
Rockwell Medical Schedules Second Quarter 2016 Earnings Call
GlobeNewswire - Wed Aug 03, 1:31PM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss second quarter 2016 financial results on Monday, August 8, 2016 at 4:30pm Eastern Time.
RMTI: 7.21 (-0.01)
Uptrend Call Working As Rockwell Medical Technologies Stock Rises 23.7% (RMTI)
Comtex SmarTrend(R) - Thu Jun 09, 1:18AM CDT
SmarTrend identified an Uptrend for Rockwell Medical Technologies (NASDAQ:RMTI) on March 31st, 2016 at $7.83. In approximately 2 months, Rockwell Medical Technologies has returned 23.71% as of today's recent price of $9.68.
RMTI: 7.21 (-0.01)
Shares of RMTI Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:50PM CDT
SmarTrend identified an Uptrend for Rockwell Medical Technologies (NASDAQ:RMTI) on March 31st, 2016 at $7.83. In approximately 2 months, Rockwell Medical Technologies has returned 23.45% as of today's recent price of $9.66.
RMTI: 7.21 (-0.01)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 17.70 (-0.63), TXMD: 6.99 (-0.04), RMTI: 7.21 (-0.01), SNY: 39.18 (+0.77)
Shares of RMTI Up 16.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon May 23, 1:19PM CDT
SmarTrend identified an Uptrend for Rockwell Medical Technologies (NASDAQ:RMTI) on March 31st, 2016 at $7.83. In approximately 2 months, Rockwell Medical Technologies has returned 16.80% as of today's recent price of $9.14.
RMTI: 7.21 (-0.01)
Rockwell Medical Announces Multiple International Trademark Approvals for Triferic(R)
GlobeNewswire - Thu May 12, 7:00AM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received Grant of Protection relating to International Trademark Registration in multiple countries, including China, Japan, South Korea, Hong Kong, Philippines, Colombia, Australia and New Zealand on the Triferic(R) trademark. Triferic is the Company's innovative iron-replacement drug for the treatment of anemia in chronic kidney disease patients receiving hemodialysis.
RMTI: 7.21 (-0.01)
Rockwell Medical reports 1Q loss
Automated Insights - Tue May 10, 4:44PM CDT
WIXOM, Mich. (AP) _ Rockwell Medical Inc. (RMTI) on Tuesday reported a loss of $4.8 million in its first quarter.
RMTI: 7.21 (-0.01)
Rockwell Medical Reports First Quarter Results
GlobeNewswire - Tue May 10, 4:06PM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter of 2016.
RMTI: 7.21 (-0.01)
Robbins Arroyo LLP: Rockwell Medical, Inc. (RMTI) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Thu May 05, 1:17PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Rockwell Medical, Inc. (NASDAQGM: RMTI) in the U.S. District Court for the Southern District of New York. The plaintiff brings the complaint on behalf of all purchasers of Rockwell Medical securities between November 19, 2014 and February 29, 2016, for alleged violations of the Securities Act of 1934 by Rockwell Medical's officers and directors. Rockwell Medical operates as an integrated biopharmaceutical company in the United States and internationally.
RMTI: 7.21 (-0.01)
Rockwell Medical Schedules First Quarter 2016 Earnings Call
GlobeNewswire - Thu May 05, 7:01AM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss first quarter 2016 financial results on Tuesday, May 10, 2016 at 4:30pm Eastern Time.
RMTI: 7.21 (-0.01)
Rockwell Medical Provides Update on Preparations for Calcitriol Commercial Launch
GlobeNewswire - Wed May 04, 7:00AM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today provided an update on preparations for the commercial launch of Calcitriol, its FDA approved active vitamin D injection for the management of hypocalcemia in patients undergoing chronic renal dialysis.
RMTI: 7.21 (-0.01)
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Rockwell Medical, Inc.
BusinessWire - Tue May 03, 5:33PM CDT
Glancy Prongay & Murray LLP ("GPM"
announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of a class (the "Class" of purchasers of Rockwell Medical, Inc. ("Rockwell" or the "Company" (NASDAQ: RMTI) securities between November 19, 2014 and February 29, 2016, inclusive (the "Class Period".
RMTI: 7.21 (-0.01)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Rockwell Medical, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2016
BusinessWire - Mon May 02, 3:54PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
RMTI: 7.21 (-0.01)
GPM Reminds Investors of the May 3 Deadline in the Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors to Contact the Firm
BusinessWire - Mon May 02, 12:04PM CDT
Glancy Prongay & Murray LLP ("GPM" reminds investors of the upcoming May 3, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Rockwell Medical, Inc. ("Rockwell Medical" or the "Company" (NASDAQ: RMTI) securities between September 9, 2015 through February 29, 2016, inclusive (the "Class Period". Rockwell Medical investors have until May 3, 2016 to file a lead plaintiff motion.
RMTI: 7.21 (-0.01)
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Rockwell Medical, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline -- RMTI
GlobeNewswire - Mon May 02, 11:10AM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Rockwell Medical, Inc. ("Rockwell" or the "Company" (NASDAQ:RMTI) of the May 3, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
RMTI: 7.21 (-0.01)
Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming May 3 Deadline in the Securities Class Action Against Rockwell Medical, Inc. and Encourages Investors to Contact the Firm
BusinessWire - Fri Apr 29, 1:26PM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming May 3, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Rockwell Medical, Inc. ("Rockwell Medical" or the "Company" (NASDAQ: RMTI) securities between September 9, 2015 through February 29, 2016, inclusive (the "Class Period". Rockwell Medical investors have until May 3, 2016 to file a lead plaintiff motion.
RMTI: 7.21 (-0.01)
ALERT: Rosen Law Firm Reminds Rockwell Medical, Inc. Investors of Important May 3, 2016 Deadline in Class Action Filed by Firm - RMTI
GlobeNewswire - Fri Apr 22, 3:08PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers Rockwell Medical, Inc. securities (NASDAQ:RMTI) from September 9, 2015 through February 29, 2016, both dates inclusive (the "Class Period" of the important May 3, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Rockwell Medical investors under the federal securities laws.
RMTI: 7.21 (-0.01)
Rockwell Medical Enters into Exclusive License Agreement with ARAM Medical to Commercialize Triferic(R) in Saudi Arabia, Egypt and Middle East Territories
GlobeNewswire - Tue Aug 16, 7:00AM CDT
- Territory Covers 375,000 CKD-HD patients; Rockwell Receives Upfront Licensing Fee,
RMTI: 7.21 (-0.01)
Rockwell Medical Reports Second Quarter Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2016.
RMTI: 7.21 (-0.01)
Rockwell Medical Schedules Second Quarter 2016 Earnings Call
GlobeNewswire - Wed Aug 03, 1:31PM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss second quarter 2016 financial results on Monday, August 8, 2016 at 4:30pm Eastern Time.
RMTI: 7.21 (-0.01)
Uptrend Call Working As Rockwell Medical Technologies Stock Rises 23.7% (RMTI)
Comtex SmarTrend(R) - Thu Jun 09, 1:18AM CDT
SmarTrend identified an Uptrend for Rockwell Medical Technologies (NASDAQ:RMTI) on March 31st, 2016 at $7.83. In approximately 2 months, Rockwell Medical Technologies has returned 23.71% as of today's recent price of $9.68.
RMTI: 7.21 (-0.01)
Shares of RMTI Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:50PM CDT
SmarTrend identified an Uptrend for Rockwell Medical Technologies (NASDAQ:RMTI) on March 31st, 2016 at $7.83. In approximately 2 months, Rockwell Medical Technologies has returned 23.45% as of today's recent price of $9.66.
RMTI: 7.21 (-0.01)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 17.70 (-0.63), TXMD: 6.99 (-0.04), RMTI: 7.21 (-0.01), SNY: 39.18 (+0.77)
Shares of RMTI Up 16.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon May 23, 1:19PM CDT
SmarTrend identified an Uptrend for Rockwell Medical Technologies (NASDAQ:RMTI) on March 31st, 2016 at $7.83. In approximately 2 months, Rockwell Medical Technologies has returned 16.80% as of today's recent price of $9.14.
RMTI: 7.21 (-0.01)
Rockwell Medical Announces Multiple International Trademark Approvals for Triferic(R)
GlobeNewswire - Thu May 12, 7:00AM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received Grant of Protection relating to International Trademark Registration in multiple countries, including China, Japan, South Korea, Hong Kong, Philippines, Colombia, Australia and New Zealand on the Triferic(R) trademark. Triferic is the Company's innovative iron-replacement drug for the treatment of anemia in chronic kidney disease patients receiving hemodialysis.
RMTI: 7.21 (-0.01)
Rockwell Medical reports 1Q loss
Automated Insights - Tue May 10, 4:44PM CDT
WIXOM, Mich. (AP) _ Rockwell Medical Inc. (RMTI) on Tuesday reported a loss of $4.8 million in its first quarter.
RMTI: 7.21 (-0.01)
Rockwell Medical Reports First Quarter Results
GlobeNewswire - Tue May 10, 4:06PM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter of 2016.
RMTI: 7.21 (-0.01)
Robbins Arroyo LLP: Rockwell Medical, Inc. (RMTI) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Thu May 05, 1:17PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Rockwell Medical, Inc. (NASDAQGM: RMTI) in the U.S. District Court for the Southern District of New York. The plaintiff brings the complaint on behalf of all purchasers of Rockwell Medical securities between November 19, 2014 and February 29, 2016, for alleged violations of the Securities Act of 1934 by Rockwell Medical's officers and directors. Rockwell Medical operates as an integrated biopharmaceutical company in the United States and internationally.
RMTI: 7.21 (-0.01)
Rockwell Medical Schedules First Quarter 2016 Earnings Call
GlobeNewswire - Thu May 05, 7:01AM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss first quarter 2016 financial results on Tuesday, May 10, 2016 at 4:30pm Eastern Time.
RMTI: 7.21 (-0.01)
Rockwell Medical Provides Update on Preparations for Calcitriol Commercial Launch
GlobeNewswire - Wed May 04, 7:00AM CDT
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today provided an update on preparations for the commercial launch of Calcitriol, its FDA approved active vitamin D injection for the management of hypocalcemia in patients undergoing chronic renal dialysis.
RMTI: 7.21 (-0.01)
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Rockwell Medical, Inc.
BusinessWire - Tue May 03, 5:33PM CDT
Glancy Prongay & Murray LLP ("GPM"
announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of a class (the "Class" of purchasers of Rockwell Medical, Inc. ("Rockwell" or the "Company" (NASDAQ: RMTI) securities between November 19, 2014 and February 29, 2016, inclusive (the "Class Period". RMTI: 7.21 (-0.01)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Rockwell Medical, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2016
BusinessWire - Mon May 02, 3:54PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
RMTI: 7.21 (-0.01)
GPM Reminds Investors of the May 3 Deadline in the Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors to Contact the Firm
BusinessWire - Mon May 02, 12:04PM CDT
Glancy Prongay & Murray LLP ("GPM"
reminds investors of the upcoming May 3, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Rockwell Medical, Inc. ("Rockwell Medical" or the "Company" (NASDAQ: RMTI) securities between September 9, 2015 through February 29, 2016, inclusive (the "Class Period". Rockwell Medical investors have until May 3, 2016 to file a lead plaintiff motion. RMTI: 7.21 (-0.01)
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Rockwell Medical, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline -- RMTI
GlobeNewswire - Mon May 02, 11:10AM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Rockwell Medical, Inc. ("Rockwell" or the "Company"
(NASDAQ:RMTI) of the May 3, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. RMTI: 7.21 (-0.01)
Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming May 3 Deadline in the Securities Class Action Against Rockwell Medical, Inc. and Encourages Investors to Contact the Firm
BusinessWire - Fri Apr 29, 1:26PM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming May 3, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Rockwell Medical, Inc. ("Rockwell Medical" or the "Company"
(NASDAQ: RMTI) securities between September 9, 2015 through February 29, 2016, inclusive (the "Class Period". Rockwell Medical investors have until May 3, 2016 to file a lead plaintiff motion. RMTI: 7.21 (-0.01)
ALERT: Rosen Law Firm Reminds Rockwell Medical, Inc. Investors of Important May 3, 2016 Deadline in Class Action Filed by Firm - RMTI
GlobeNewswire - Fri Apr 22, 3:08PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers Rockwell Medical, Inc. securities (NASDAQ:RMTI) from September 9, 2015 through February 29, 2016, both dates inclusive (the "Class Period"
of the important May 3, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Rockwell Medical investors under the federal securities laws. RMTI: 7.21 (-0.01)
